West Pharmaceutical Services, Inc.

BRSE:WPS Stock Report

Market Cap: CHF 19.3b

West Pharmaceutical Services Valuation

Is WPS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of WPS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: WPS (CHF273.98) is trading below our estimate of future cash flow value (CHF297.33)

Significantly Below Future Cash Flow Value: WPS is trading below future cash flow value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for WPS?

Key metric: As WPS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for WPS. This is calculated by dividing WPS's market cap by their current earnings.
What is WPS's PE Ratio?
PE Ratio42x
EarningsUS$564.90m
Market CapUS$23.72b

Price to Earnings Ratio vs Peers

How does WPS's PE Ratio compare to its peers?

The above table shows the PE ratio for WPS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average44.2x
LONN Lonza Group
37.1x17.28%CHF 40.1b
BANB Bachem Holding
37.1x16.06%CHF 5.5b
SFZN Siegfried Holding
20x9.95%CHF 3.4b
SKAN SKAN Group
82.6x28.79%CHF 1.3b
WPS West Pharmaceutical Services
42x11.10%CHF 23.7b

Price-To-Earnings vs Peers: WPS is good value based on its Price-To-Earnings Ratio (42x) compared to the peer average (44.2x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does WPS's PE Ratio compare vs other companies in the European Life Sciences Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
WPS 42.0xIndustry Avg. 37.1xNo. of Companies2PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: WPS is expensive based on its Price-To-Earnings Ratio (42x) compared to the Global Life Sciences industry average (36.5x).

Price to Earnings Ratio vs Fair Ratio

What is WPS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

WPS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio42x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate WPS's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst WPS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 273.98
CHF 330.87
+20.76%
6.33%CHF 375.97CHF 278.50n/a15
Jul ’27CHF 291.70
CHF 292.70
+0.34%
7.36%CHF 323.74CHF 250.90n/a14
Jun ’27n/a
CHF 277.17
0%
7.29%CHF 314.64CHF 243.85n/a14
May ’27n/a
CHF 274.86
0%
7.64%CHF 314.26CHF 243.55n/a13
Apr ’27n/a
CHF 250.71
0%
8.82%CHF 296.87CHF 209.79n/a13
Mar ’27n/a
CHF 246.12
0%
8.66%CHF 289.91CHF 204.87n/a14
Feb ’27n/a
CHF 275.77
0%
7.65%CHF 311.10CHF 227.34n/a14
Jan ’27n/a
CHF 275.00
0%
7.65%CHF 310.23CHF 226.70n/a14
Dec ’26n/a
CHF 278.53
0%
7.63%CHF 313.89CHF 229.38n/a14
Nov ’26n/a
CHF 282.25
0%
5.99%CHF 313.81CHF 249.44n/a13
Oct ’26n/a
CHF 248.43
0%
8.06%CHF 275.24CHF 204.46n/a12
Sep ’26n/a
CHF 255.92
0%
8.39%CHF 283.13CHF 210.33n/a11
Aug ’26n/a
CHF 254.11
0%
8.39%CHF 281.12CHF 208.83n/a11
Jul ’26n/a
CHF 224.38
0%
9.56%CHF 261.52CHF 197.15CHF 291.7012
Jun ’26n/a
CHF 231.94
0%
9.12%CHF 267.39CHF 201.57n/a11
May ’26n/a
CHF 233.34
0%
9.09%CHF 269.08CHF 202.85n/a11
Apr ’26n/a
CHF 251.92
0%
8.95%CHF 287.26CHF 212.13n/a10
Mar ’26n/a
CHF 255.96
0%
9.34%CHF 293.42CHF 216.68n/a10
Feb ’26n/a
CHF 346.19
0%
10.42%CHF 428.35CHF 277.97n/a10
Jan ’26n/a
CHF 339.84
0%
10.88%CHF 422.37CHF 274.09n/a9
Dec ’25n/a
CHF 312.72
0%
14.68%CHF 406.50CHF 229.20n/a9
Nov ’25n/a
CHF 312.72
0%
14.68%CHF 406.50CHF 229.20n/a9
Oct ’25n/a
CHF 311.81
0%
15.30%CHF 416.51CHF 234.84n/a9
Sep ’25n/a
CHF 311.81
0%
15.30%CHF 416.51CHF 234.84n/a9
Aug ’25n/a
CHF 311.81
0%
15.30%CHF 416.51CHF 234.84n/a9
Jul ’25n/a
CHF 356.45
0%
9.39%CHF 421.44CHF 301.28n/a9
CHF 327.95
Fair Value
16.5% undervalued intrinsic discount
15
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/29 17:42
End of Day Share Price 2026/07/29 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

West Pharmaceutical Services, Inc. is covered by 27 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Luke SergottBarclays
Lawrence MarshBarclays
Curtis MoilesBNP Paribas